Product Name: ARA-290 (Cibinetide Acetate) - 16mg
CAS Number: 1208243-50-8
Molecular Formula: C₅₁H₈₄N₁₆O₂₁
Molecular Weight: 1257.3 g/mol
Purity: ≥99% (HPLC verified)
Form: Lyophilized white powder
 
 
Product Overview:
 
ARA-290, also known as Cibinetide, represents a breakthrough in peptide research and neuroprotective therapy. This innovative 11-amino acid peptide is derived from the helix beta domain of erythropoietin (EPO), specifically engineered to deliver the therapeutic benefits of EPO without stimulating red blood cell production.
 
Key Sequence: Pyroglutamic acid-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
 
Unlike traditional EPO therapy, ARA-290 selectively activates the Innate Repair Receptor (IRR), also known as the tissue-protective receptor (TPR), which mediates anti-inflammatory responses and tissue regeneration without hematopoietic side effects.
Research-Backed Mechanisms & Benefits
 
Neuroprotective Effects
 
ARA-290 has demonstrated exceptional efficacy in clinical trials for treating neuropathic pain conditions. In Phase II studies with diabetic neuropathy patients, daily administration of 4mg ARA-290 showed significant improvement in neuropathic symptoms as measured by the PainDetect questionnaire, with sustained benefits lasting weeks after treatment completion.
 
Clinical Evidence:
Diabetic Neuropathy: 28-day treatment with 4mg daily improved HbA1c levels and reduced neuropathic pain symptoms
Sarcoidosis Neuropathy: Patients receiving 2mg intravenous ARA-290 three times weekly showed significant improvement in Small Fiber Neuropathy Screening List (SFNSL) scores compared to placebo
Corneal Nerve Regeneration: Increased corneal nerve fiber density observed in patients with baseline deficiencies
Phases of skin wound healing showing cellular responses and collagen production during inflammatory, proliferative, and remodeling stages 
 
Anti-Inflammatory & Tissue Protection
 
Research demonstrates that ARA-290 significantly reduces harmful inflammatory cytokines including IL-6, IL-12, and TNF-alpha. This anti-inflammatory action protects transplanted tissues, promotes wound healing, and supports cardiovascular health.
 
Proven Applications:
Suppression of macrophage activation for improved islet cell transplant survival
Enhanced endothelial colony-forming cell (ECFC) function for vascular repair
Accelerated wound healing in diabetic models
Reduced organ transplant rejection rates
 
Metabolic Benefits
 
Clinical trials reveal ARA-290's capacity to improve glucose control and lipid profiles. Diabetic patients showed sustained improvements in HbA1c levels and cholesterol-HDL ratios, with increased HDL levels and improved triglyceride concentrations.
Dosage & Administration Protocols
 
Lyophilized Powder Storage:
Long-term: Store at -20°C or below for maximum stability
Short-term: 4°C refrigeration acceptable for weeks to months
Room temperature: Stable for days to weeks (emergency only)
Protection: Keep away from light and moisture
 
Reconstitution Protocol:
Allow vial to reach room temperature before opening to prevent moisture uptake
Reconstitute with sterile bacteriostatic water or sterile saline
Use aseptic technique throughout reconstitution process
Gentle swirling recommended; avoid vigorous shaking
 
Safety Profile & Clinical Considerations
ARA-290 has demonstrated an excellent safety profile across multiple clinical trials. No significant adverse events were reported during Phase II studies, with no clinically relevant changes in hematological or biochemical parameters.
 
Notable Safety Features:
No erythropoietic activity (no increased red blood cell production)
No cardiovascular side effects associated with EPO therapy
Well-tolerated in repeated dosing protocols
No anti-ARA-290 antibody formation observed
 
Potential Interactions:
May affect loop diuretic activity - dosage adjustments may be required
Patients with renal issues should consult healthcare providers
 
Manufacturing Standards:
Synthesized using advanced solid-phase peptide synthesis
Purified via high-performance liquid chromatography (HPLC)
Verified ≥99% purity through analytical testing
Lyophilized under sterile conditions
Packaged in sterile, vacuum-sealed vials
 
 
Research Applications & Future Directions
ARA-290 is currently advancing through Phase III clinical trials for multiple indications. The FDA has granted Orphan Drug Status for painful sarcoid neuropathy treatment, highlighting its significant therapeutic potential.
Active Research Areas:
Diabetic Macular Edema: Phase II trials investigating retinal protection
Systemic Lupus Erythematosus: Autoantibody suppression and kidney protection
Inflammatory Bowel Disease: Immune modulation for Crohn's and ulcerative colitis
Organ Transplantation: Reducing rejection and improving graft survival
 
Why Choose PeptidesAlpha for ARA-290?
At PeptidesAlpha, we pride ourselves on delivering pharmaceutical-grade research peptides with uncompromising quality standards. Our ARA-290 is:
✓ Pharmaceutical Grade - Manufactured under strict GMP conditions
✓ Rigorously Tested - Each batch undergoes comprehensive analytical verification
✓ Properly Stored - Maintained in optimal conditions until shipment
✓ Research Focused - Designed for serious researchers and institutions
✓ Competitively Priced - Premium quality without premium pricing
 
Important Notice: This product is intended for research purposes only. Not for human consumption. Must be handled by qualified researchers in appropriate laboratory settings.
ARA-290 represents the future of targeted neuroprotective therapy, offering researchers unprecedented opportunities to investigate novel treatments for neuropathic pain, inflammatory conditions, and tissue repair. 
 
Trust PeptidesAlpha for your critical research needs.